Avecho Biotechnology (AVE) H2 2025 earnings summary

Executive summary

• Revenue increased 9.3% year-over-year to $1,237,762, driven mainly by Vital ETⓇ sales and licensing activities.

• Net loss widened 41.5% to $4,416,623, reflecting higher R&D and administrative expenses typical for biotech firms at this stage.

• Major milestone: Signed a licensing agreement with Sandoz AG for exclusive Australian rights to the CBD insomnia capsule, receiving a $4.8M upfront payment and eligibility for up to $16M in milestones plus royalties.

• Raised $2.5M via placement to accelerate commercial manufacturing and support regulatory submissions.

Financial highlights

• Revenue from ordinary activities: $1,237,762 (up 9% year-over-year).

• Net loss after tax: $4,416,623 (vs. $3,122,048 in 2024).

• R&D tax incentives: $1,995,884 (up from $1,635,464 in 2024).

• Cash and cash equivalents: $4,663,491 at year-end (vs. $2,374,534 prior year).

• Net tangible assets per share: 0.04 cents (down from 0.10 cents in 2024).

Outlook and guidance

• Interim analysis for the Phase III CBD insomnia trial targeted for completion in H1 2026, expected to be a major inflection point.

• Ongoing recruitment for the trial, with expanded sites and protocol amendments to accelerate progress.

• Focus on securing additional international licensing agreements beyond Australia.